INSIGHT MRL: Phase I Trial of INtenSIfication of Glioblastoma Hypofractionated Treatment on the MR-Linac

Brief description of study

This is a phase 1 study to examine the safety and tolerability of biology-guided dose intensified hypofractionated radiation therapy (RT) using MR-Linac for patients with high grade glioma (HGG). We will enroll 20 patients with Grade 3 or 4, IDH wildtype

Clinical Study Identifier: s25-01305

ClinicalTrials.gov Identifier: NCT07457307

Principal Investigator: Jonathan Tzu-l Yang.

Other Investigators: Caitlin Elizabeth Ordonez Ferri, Minerva A Utate, Jessica D. Schulte, Alexandra M. Miller, Alexandra Gewirtz, Dimitris G Placantonakis, Neil L. Sielski, Jessica Goggin, Lynda Julie Boulio-Castillo, Jennifer H Fisher, Daniel A. Orringer, Benjamin Cooper, Jacqueline Li, Ryan C Mitchell, Marissa Barbaro, Joshua S. Silverman, John G Golfinos, Jose Ricardo McFaline Figueroa.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies